The vitamin D analogue 2MD increases bone turnover but not BMD in postmenopausal women with osteopenia: Results of a 1-year phase 2 double-blind, placebo-controlled, randomized clinical trial

Journal of Bone and Mineral Research

Volumn 26, Issue 3, 2011, Pages 538-545

  Deluca, Hector F ^a   Bedale, Wendy ^a   Binkley, Neil ^a   Gallagher, J Chris ^b   Bolognese, Michael ^c   Peacock, Munro ^d   Aloia, John ^e   Clagett Dame, Margaret ^a   Plum, Lori ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^c Bone Health Center of Bethesda   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

2MD; BMD; bone; Osteoporosis; vitamin D

Indexed keywords

2 METHYLENE 19 NOR 1ALPHA,25 DIHYDROXYVITAMIN D3; CARBOXY TERMINAL TELOPEPTIDE; COLECALCIFEROL; COLLAGEN TYPE 1; OSTEOCALCIN; PARATHYROID HORMONE; PLACEBO; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; OSTEOPENIA; PARATHYROID HORMONE BLOOD LEVEL; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VOLUNTEER;

ANIMALS; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; BONE REMODELING; CALCITRIOL; CALCIUM; DEMOGRAPHY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; PARATHYROID HORMONE; PLACEBOS; POSTMENOPAUSE; RATS; VITAMIN D;

EID: 78649717331     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.256     Document Type: Article

References (50)

1. Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB,. Incidence and mortality of hip fractures in the United States. JAMA. 2009; 302: 1573-1579.
2. Lewiecki EM,. Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis. J Womens Health (Larchmt). 2009; 18: 1615-1626.
3. Chesnut CH III, Azria M, Silverman S, Engelhardt M, Olson M, Mindeholm L,. Salmon calcitonin: a review of current and future therapeutic indications. Osteoporos Int. 2008; 19: 479-491.
4. de Nijs RN, Jacobs JW, Lems WF, et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med. 2006; 355: 675-684.
5. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008; 148: 197-213. (Pubitemid 351665507)
6. Tilyard MW, Spears GF, Thomson J, Dovey S,. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med. 1992; 326: 357-362.
7. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006; 354: 821-831. (Pubitemid 43290920)
8. Hattner R, Epker BN, Frost HM,. Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling. Nature. 1965; 206: 489-490.
9. Gallagher JC, Sai AJ,. Molecular biology of bone remodeling: implications for new therapeutic targets for osteoporosis. Maturitas. 2010; 65: 301-307.
10. Reeve J,. Teriparatide and Future Anabolic Treatments for Osteoporosis. In:, Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism Fifth ed. Washington, DC: American Society for Bone and Mineral Research, 2003.
11. Gallagher JC, Goldgar D,. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Intern Med. 1990; 113: 649-655. (Pubitemid 20363636)
12. Ott SM, Chesnut CH 3rd., Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Intern Med. 1989; 110: 267-274. (Pubitemid 19062154)
13. Papadimitropoulos E, Wells G, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev. 2002; 23: 560-569. (Pubitemid 34925650)
14. O'Donnell S, Moher D, Thomas K, Hanley DA, Cranney A,. Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls. J Bone Miner Metab. 2008; 26: 531-542.
15. Gallagher JC, Riggs BL, Recker RR, Goldgar D,. The effect of calcitriol on patients with postmenopausal osteoporosis with special reference to fracture frequency. Proceedings of the Society for Experimental Biology & Medicine. 1989; 191: 287-292. (Pubitemid 19176119)
16. Orimo H, Shiraki M, Hayashi T, Nakamura T,. Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with 1 alpha (OH)-vitamin D3. Bone & Mineral. 1987; 3: 47-52. (Pubitemid 18039736)
17. Uchiyama Y, Higuch IY, Takeda S, et al. ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone. 2002; 30: 582-588. (Pubitemid 34270495)
18. Erben RG, Mosekilde L, Thomsen JS, et al. Prevention of bone loss in ovariectomized rats by combined treatment with risedronate and 1alpha,25-dihydroxyvitamin D3. Journal of Bone & Mineral Research. 2002; 17: 1498-1511. (Pubitemid 34803833)
19. Sicinski RR, Prahl JM, Smith CM, DeLuca HF,. New 1alpha,25-dihydroxy-19- norvitamin D3 compounds of high biological activity: synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl, and 2-methylene analogues. J Med Chem. 1998; 41: 4662-4674. (Pubitemid 28516465)
20. Ke HZ, Qi H, Crawford DT, et al. A new vitamin D analog, 2MD, restores trabecular and cortical bone mass and strength in ovariectomized rats with established osteopenia. J Bone Miner Res. 2005; 20: 1742-1755. (Pubitemid 41361875)
21. Plum LA, Fitzpatrick LA, Ma X, et al. 2MD, a new anabolic agent for osteoporosis treatment. Osteoporos Int. 2006; 17: 704-715.
22. Shevde NK, Plum LA, Clagett-Dame M, Yamamoto H, Pike JW, DeLuca HF,. A potent analog of 1alpha,25-dihydroxyvitamin D3 selectively induces bone formation. Proc Natl Acad Sci USA. 2002; 99: 13487-13491. (Pubitemid 35215408)
23. Guidelines for Preclinical Evaluation and Clinical Trials in Osteoporosis. World Health Organization, Geneva 1998.
24. 2006 Guideline on the Evaluation of Medicinal Products in the Treatment of Primary Osteoporosis. European Medicines Agency, London.
25. 1994 Guidelines for the Preclinical and Clinical Evaluation of Agents Used in the Prevention or Treatment of Postmenopausal Osteoporosis. Division of Metabolic and Endocrine Drug Products, Food and Drug Administration, Rockville, MD.
26. Parfitt AM,. The cellular basis of bone remodeling: the quantum concept reexamined in light of recent advances in the cell biology of bone. Calcif Tissue Int. 1984; 36 (Suppl 1): S37-45. (Pubitemid 14043313)
27. Frost HM,. Bone Remodelling Dynamics. Springfield, IL: Charles C. Thomas, 1963.
28. Lelovas PP, Xanthos TT, Thoma SE, Lyritis GP, Dontas IA,. The laboratory rat as an animal model for osteoporosis research. Comp Med. 2008; 58: 424-430.
29. Chow JW, Badve S, Chambers TJ,. A comparison of microanatomic basis for coupling between bone formation and bone resorption in man and the rat. Bone. 1993; 14: 355-360. (Pubitemid 23175752)
30. Chow JW, Badve S, Chambers TJ,. Bone formation is not coupled to bone resorption in a site-specific manner in adult rats. Anat Rec. 1993; 236: 366-372. (Pubitemid 23148426)
31. Stone KL, Seeley DG, Lui LY, et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res. 2003; 18: 1947-1954. (Pubitemid 37377443)
32. Divittorio G, Jackson KL, Chindalore VL, Welker W, Walker JB,. Examining the relationship between bone mineral density and fracture risk reduction during pharmacologic treatment of osteoporosis. Pharmacotherapy. 2006; 26: 104-114. (Pubitemid 43082931)
33. Faulkner KG,. Bone matters: are density increases necessary to reduce fracture risk? J Bone Miner Res. 2000; 15: 183-187. (Pubitemid 30095704)
34. Leslie WD, Metge C, Salamon EA, Yuen CK,. Bone mineral density testing in healthy postmenopausal women. The role of clinical risk factor assessment in determining fracture risk. J Clin Densitom. 2002; 5: 117-130.
35. Alexander JM, Bab I, Fish S, et al. Human parathyroid hormone 1-34 reverses bone loss in ovariectomized mice. J Bone Miner Res. 2001; 16: 1665-1673. (Pubitemid 32786436)
36. Wronski TJ, Yen CF, Scott KS,. Estrogen and diphosphonate treatment provide long-term protection against osteopenia in ovariectomized rats. J Bone Miner Res. 1991; 6: 387-394.
37. Black LJ, Sato M, Rowley ER, et al. et al. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest. 1994; 93: 63-69. (Pubitemid 24030821)
38. Lyons RA, Johansen A, Brophy S, et al. Preventing fractures among older people living in institutional care: a pragmatic randomised double blind placebo controlled trial of vitamin D supplementation. Osteoporos Int. 2007; 18: 811-818. (Pubitemid 46684786)
39. Grant AM, Avenell A, Campbell MK, et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet. 2005; 365: 1621-1628. (Pubitemid 40693411)
40. Richy F, Schacht E, Bruyere O, Ethgen O, Gourlay M, Reginster JY,. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis. Calcif Tissue Int. 2005; 76: 176-186. (Pubitemid 41557146)
41. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B,. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005; 293: 2257-2264. (Pubitemid 40629192)
42. Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ 340: b5463 2010.
43. Avenell A, Gillespie WJ, Gillespie LD, O'Connell D,. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev. 2009; (2): CD000227.
44. Kubodera N,. D-hormone derivatives for the treatment of osteoporosis: from alfacalcidol to eldecalcitol. Mini Rev Med Chem. 2009; 9: 1416-1422.
45. Matsumoto T, Miki T, Hagino H, et al. A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2005; 90: 5031-5036. (Pubitemid 41262250)
46. Bauer DC, Garnero P, Hochberg MC, et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res. 2006; 21: 292-299. (Pubitemid 43265295)
47. Obermayer-Pietsch BM, Marin F, McCloskey EV, et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res. 2008; 23: 1591-1600.
48. Middleton ET, Steel SA, Aye M, Doherty SM,. The effect of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate. J Bone Miner Res. 2009; 25: 455-462.
49. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY,. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005; 90: 1294-1301. (Pubitemid 40463979)
50. Barnes GL, Kakar S, Vora S, Morgan EF, Gerstenfeld LC, Einhorn TA,. Stimulation of fracture-healing with systemic intermittent parathyroid hormone treatment. J Bone Joint Surg Am. 2008; 90 (Suppl 1): 120-127. (Pubitemid 351329130)